Drug Trial Radar · NCT02961764
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Last checked: Nov 19, 2026Latest source record: Apr 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
313
Actual
Start
Nov 29, 2016
Primary completion
Mar 29, 2019
Study completion Mar 29, 2019
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.
Conditions
- Acute Bacterial Skin and Skin Structure Infections
Interventions
Usual CareDrug
Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
DalbavancinDrug
Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospital Admission Rate at Initial Episode of CareTime frame: 44 Days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Maricopa Medical Center
Phoenix, Arizona
Olive View-UCLA Medical Center
Sylmar, California
Hartford Hospital
Hartford, Connecticut
Tampa General Hospital
Tampa, Florida
Rush University Medical Center
Chicago, Illinois
Johns Hopkins Hospital
Baltimore, Maryland
University of Massachusetts
Worcester, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Wayne State University
Detroit, Michigan
ProMedica Monroe Regional Hospital
Monroe, Michigan
Truman Medical Centers
Kansas City, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.